Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti‐HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients

Podobne knjige/članki

• Streptococcus pyogenes Infection and the Human Proteome with a Special Focus on the Immunoglobulin G-cleaving Enzyme IdeS
  od: Karlsson, Christofer A. Q., et al.
  Izdano: (2018)
• Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes)
  od: Jordan, Stanley C., et al.
  Izdano: (2021)
• The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation
  od: Järnum, Sofia, et al.
  Izdano: (2015)
• Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity
  od: Winstedt, Lena, et al.
  Izdano: (2015)
• Desensitization using imlifidase and EndoS enables chimerism induction in allosensitized recipient mice
  od: Lin, Jiaxin, et al.
  Izdano: (2020)